Noninvasive Prenatal Testing of Single Gene Diseases Developed
By LabMedica International staff writers Posted on 01 Feb 2017 |
Image: A Single Nucleotide Polymorphism (SNP) is a change of a nucleotide at a single base-pair location on DNA. The upper DNA molecule differs from the lower DNA molecule at a single base-pair location (a C/A polymorphism) (Photo courtesy of David Eccles).
An approach that allows for the noninvasive assessment of both maternally and paternally inherited mutations involves the analysis of single nucleotide polymorphisms (SNPs) in maternal plasma DNA with reference to parental haplotype information.
In the past, parental haplotypes were resolved by complex investigational methods or inferential approaches, such as through the analysis of DNA from other affected family members. Recently, microfluidics-based linked-read sequencing technology has become available and allows the direct haplotype phasing of the whole genome rapidly.
Scientists at the Chinese University of Hong Kong developed a test that can detect almost any single-gene disorder in the first six to 10 weeks of pregnancy. Guided by DNA from parent blood samples, the test looks for increases in the level of mutations associated with a particular condition in the mother’s blood once she is pregnant. In theory, any hospital pathology laboratory could run the test, producing results in one to two weeks.
The team first resolved the haplotypes of parental genomes with the use of linked-read sequencing technology. Then, they identified single nuclear polymorphisms (SNPs) within and flanking the genes of interest in maternal plasma DNA by targeted sequencing. Finally, they applied relative haplotype dosage analysis to deduce the mutation inheritance status of the fetus. They reported that haplotype phasing and relative haplotype dosage analysis of 12 out of 13 families were successfully achieved. The mutational status of these 12 fetuses was correctly classified.
The authors concluded that high-throughput linked-read sequencing followed by maternal plasma-based relative haplotype dosage analysis represents a streamlined approach for noninvasive prenatal testing of inherited single gene diseases. The approach bypasses the need for mutation-specific assays and is not dependent on the availability of DNA from other affected family members. Thus, the approach is universally applicable to pregnancies at risk for the inheritance of a single gene disease. The study was published in the January 2017 issue of the journal Clinical Chemistry.
In the past, parental haplotypes were resolved by complex investigational methods or inferential approaches, such as through the analysis of DNA from other affected family members. Recently, microfluidics-based linked-read sequencing technology has become available and allows the direct haplotype phasing of the whole genome rapidly.
Scientists at the Chinese University of Hong Kong developed a test that can detect almost any single-gene disorder in the first six to 10 weeks of pregnancy. Guided by DNA from parent blood samples, the test looks for increases in the level of mutations associated with a particular condition in the mother’s blood once she is pregnant. In theory, any hospital pathology laboratory could run the test, producing results in one to two weeks.
The team first resolved the haplotypes of parental genomes with the use of linked-read sequencing technology. Then, they identified single nuclear polymorphisms (SNPs) within and flanking the genes of interest in maternal plasma DNA by targeted sequencing. Finally, they applied relative haplotype dosage analysis to deduce the mutation inheritance status of the fetus. They reported that haplotype phasing and relative haplotype dosage analysis of 12 out of 13 families were successfully achieved. The mutational status of these 12 fetuses was correctly classified.
The authors concluded that high-throughput linked-read sequencing followed by maternal plasma-based relative haplotype dosage analysis represents a streamlined approach for noninvasive prenatal testing of inherited single gene diseases. The approach bypasses the need for mutation-specific assays and is not dependent on the availability of DNA from other affected family members. Thus, the approach is universally applicable to pregnancies at risk for the inheritance of a single gene disease. The study was published in the January 2017 issue of the journal Clinical Chemistry.
Latest Molecular Diagnostics News
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing